Logo image of VM.CA

VOYAGEUR PHARMACEUTICALS LTD (VM.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:VM - CA92918C1014 - Common Stock

0.15 CAD
0 (0%)
Last: 12/5/2025, 7:00:00 PM
Fundamental Rating

0

VM gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. VM may be in some trouble as it scores bad on both profitability and health. VM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VM has reported negative net income.
In the past year VM has reported a negative cash flow from operations.
In the past 5 years VM always reported negative net income.
In the past 5 years VM always reported negative operating cash flow.
VM.CA Yearly Net Income VS EBIT VS OCF VS FCFVM.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500K -1M -1.5M -2M

1.2 Ratios

Industry RankSector Rank
ROA -84.97%
ROE -216.61%
ROIC N/A
ROA(3y)-71.36%
ROA(5y)-76.67%
ROE(3y)-198.87%
ROE(5y)-215.24%
ROIC(3y)N/A
ROIC(5y)N/A
VM.CA Yearly ROA, ROE, ROICVM.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VM.CA Yearly Profit, Operating, Gross MarginsVM.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for VM has been increased compared to 1 year ago.
VM has more shares outstanding than it did 5 years ago.
VM has a better debt/assets ratio than last year.
VM.CA Yearly Shares OutstandingVM.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VM.CA Yearly Total Debt VS Total AssetsVM.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M

2.2 Solvency

VM has an Altman-Z score of -1.05. This is a bad value and indicates that VM is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.03 indicates that VM is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -1.05
ROIC/WACCN/A
WACCN/A
VM.CA Yearly LT Debt VS Equity VS FCFVM.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1M -1M -2M

2.3 Liquidity

A Current Ratio of 0.58 indicates that VM may have some problems paying its short term obligations.
VM has a Quick Ratio of 0.58. This is a bad value and indicates that VM is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.58
Quick Ratio 0.51
VM.CA Yearly Current Assets VS Current LiabilitesVM.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

0

3. Growth

3.1 Past

VM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -46.67%.
EPS 1Y (TTM)-46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VM. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VM.CA Price Earnings VS Forward Price EarningsVM.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VM.CA Per share dataVM.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 -0 -0.01 -0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VOYAGEUR PHARMACEUTICALS LTD

TSX-V:VM (12/5/2025, 7:00:00 PM)

0.15

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.34%
Inst Owner ChangeN/A
Ins Owners9.08%
Ins Owner ChangeN/A
Market Cap26.76M
Revenue(TTM)11.00K
Net Income(TTM)-3.13M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2432.32
P/FCF N/A
P/OCF N/A
P/B 18.54
P/tB 18.54
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -84.97%
ROE -216.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.36%
ROA(5y)-76.67%
ROE(3y)-198.87%
ROE(5y)-215.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16415.4%
Cap/Sales 1940%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.58
Quick Ratio 0.51
Altman-Z -1.05
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)9357.03%
Cap/Depr(5y)11530.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-72.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-90.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-102.93%
OCF growth 3YN/A
OCF growth 5YN/A

VOYAGEUR PHARMACEUTICALS LTD / VM.CA FAQ

What is the fundamental rating for VM stock?

ChartMill assigns a fundamental rating of 0 / 10 to VM.CA.


Can you provide the valuation status for VOYAGEUR PHARMACEUTICALS LTD?

ChartMill assigns a valuation rating of 0 / 10 to VOYAGEUR PHARMACEUTICALS LTD (VM.CA). This can be considered as Overvalued.


What is the profitability of VM stock?

VOYAGEUR PHARMACEUTICALS LTD (VM.CA) has a profitability rating of 0 / 10.